Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Observational × CYP3A Phenotyping × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Breast Neoplasms 1862 Neoplasms 1707 Lung Neoplasms 893 Colorectal Neoplasms 857 Prostatic Neoplasms 752 Carcinoma, Non-Small-Cell Lung 612 Carcinoma, Hepatocellular 563 Stomach Neoplasms 508 Pancreatic Neoplasms 500 Head and Neck Neoplasms 352 Ovarian Neoplasms 348 Colonic Neoplasms 348 Rectal Neoplasms 342 Uterine Cervical Neoplasms 331 Esophageal Neoplasms 297 Brain Neoplasms 281 Neoplasm Metastasis 268 Melanoma 257 Multiple Myeloma 253 Urinary Bladder Neoplasms 246 Precursor Cell Lymphoblastic Leukemia-Lymphoma 238 Leukemia, Myeloid, Acute 220 Lymphoma 214 Hematologic Neoplasms 214 Liver Neoplasms 206 Endometrial Neoplasms 204 Disease 195 Glioma 188 Recurrence 183 Carcinoma, Renal Cell 180

Interventions

Docetaxel 1 CEF regimen 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01110291 2010-04-27

Docetaxel

University of Turku

CYP3A Phenotyping

Data powered by HemOnc (CC BY 4.0) Colophon ⚡